@article{d6e2d3b33dd0452a8908e06a11252eb5,
title = "Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial",
abstract = "An unmet medical need exists for patients with metastatic renal cell carcinoma who have progressed on VEGF-targeted and mTOR-inhibitor therapies. Fibroblast growth factor (FGF) pathway activation has been proposed as a mechanism of escape from VEGF-targeted therapies. Dovitinib is an oral tyrosine-kinase inhibitor that inhibits VEGF and FGF receptors. We therefore compared dovitinib with sorafenib as third-line targeted therapies in patients with metastatic renal cell carcinoma.",
author = "Motzer, {Robert John} and Camillo Porta and Vogelzang, {Nicholas J} and Sternberg, {Cora N} and Cezary Szczylik and Jakub Zolnierek and Christian Kollmannsberger and Rha, {Sun Young} and Bjarnason, {Georg A} and Bohuslav Melichar and {De Giorgi}, Ugo and Viktor Grunwald and Ian Davis and Jae-Lyun Lee and Emilio Esteban and Gladys Urbanowitz and Can Cai and Matthew Squires and Marker, {Mahtab T} and Shi, {Michael M} and Bernard Escudier",
year = "2014",
doi = "10.1016/S1470-2045(14)70030-0",
language = "English",
volume = "15",
pages = "286 -- 296",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Elsevier",
number = "3",
}